Key Takeaways for Zoetis Stock as of August 2026
- Soft Print: Zoetis posted Q2 revenue of $2,468M, roughly flat YoY but down 1% organically, as a 7% US decline swamped 6% international growth.
- Guidance Cut: Management now guides full-year revenue to $9.12B–$9.32B and adjusted EPS to $6.15–$6.25, a sharp step down from its prior outlook.
- Dermatology Erosion: Key Dermatology sales fell 16% to $395M.
- Livestock Offset: Livestock grew 11% to $731M, powered by a 23% US jump tied to New World screwworm demand that management flagged as partly transitory.
Zoetis Cuts Its Full-Year Guide as Companion Animal Pressure Deepens
Zoetis (ZTS) cut its full-year outlook on the August 6 second-quarter call, and the reason sits inside its most profitable franchise. Revenue for the quarter came in at $2,468 million, flat on a reported basis and down 1% organically, with volume off 1% and price essentially unchanged.
The damage concentrated in the United States, where revenue fell 7% while international climbed 6%. Companion Animal, the company’s largest business, dropped 6% to $1.7 billion. Key Dermatology, long the crown jewel, fell 16% to $395 million as canine pruritic clinic visits kept declining and new entrants flooded the category with discounts and rebates.
That share erosion is now measurable. US in-clinic Dermatology share still sits near 86%, but it slipped 5 points sequentially and 10 points year over year. CEO Kristin Peck framed the environment plainly on the Q2 earnings call: “We are operating in a more competitive and value-conscious environment than we have seen in recent years, and we are not assuming the market gets easier.” Her fix is gross-to-net investment, targeted promotions and rebates rather than list-price cuts, meant to hold volume and defend share.
The diversified portfolio kept the quarter from breaking. Livestock grew 11% to $731 million, with US Livestock up 23% on cattle demand and New World screwworm-driven parasiticide sales, though management called much of that spike transitory. Companion Animal Diagnostics added 12% to reach $118 million.
The revised guide carries the real weight. Zoetis now expects full-year revenue of $9.12 billion to $9.32 billion, a 3% to 1% organic decline, and adjusted net income of $2.57 billion to $2.62 billion, down 9% to 5%. Adjusted EPS guidance lands at $6.15 to $6.25. Buybacks did the heavy lifting on the bottom line this quarter, as the company repurchased over $550 million of stock and lifted adjusted diluted EPS to $1.87, up 4% year over year, even while adjusted net income of $781 million fell 2% organically.
One more shift landed alongside the numbers. Longtime CFO Wetteny Joseph is departing, and Jay Saccaro, formerly CFO of GE Healthcare and Baxter, joins August 17 as EVP, CFO and COO, a newly created role built to speed decisions across finance and supply.
TIKR Values Zoetis Stock at $106, a 47% Gap to Today’s Price
TIKR’s mid-case model values Zoetis at $106 by December 2030, implying 47% total return from the current price of $73, or 9% annualized over the next 4.4 years.
A 9% annual return from a market leader trading well below its own history signals a stock the market has repriced for near-term pain rather than permanent decline.
The path back rests on the parts of the quarter that still worked. Livestock grew 11%, Diagnostics rose 12%, and international Companion Animal outgrew a shrinking US business. The model assumes gross-to-net investment stabilizes Dermatology and parasiticide share while those franchises compound, and the $106 target reflects that recovery rather than the current trough.
Should You Invest in Zoetis Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Zoetis Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Zoetis Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ZTS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
